Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2014
Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).
Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Research trends on chemotherapy induced nausea and vomiting: a bibliometric analysis.Frontiers in pharmacology · 2024Pooled it
- Clinical Applications of Substance P (Neurokinin-1 Receptor) Antagonist in Canine Medicine.Archives of Razi Institute · 2021Pooled it
- A prospective randomized controlled clinical trial investigating the efficacy of low-dose olanzapine in preventing nausea and vomiting associated with oxaliplatin-based and irinotecan-based chemotherapy.Journal of cancer research and clinical oncology · 2024Trial
- Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018Trial
- Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: A phase II study.International journal of hematology · 2017Trial
- Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Trial
- Article
- Impact of fosaprepitant in the prevention of nausea and emesis in head and neck cancer patients undergoing cisplatin-based chemoradiation: a pilot prospective study and a review of literature.La Radiologia medica · 2024Review
- Cisplatin-Induced Nausea and Vomiting: Effect of Herbal Medicines.Plants (Basel, Switzerland) · 2022Review
- Granisetron Extended-Release Subcutaneous Injection versus Palonosetron Infusion for CINV Prevention: Cost Comparison of Unscheduled Hydration.American health & drug benefits · 2021Article
- Granisetron Extended-Release Subcutaneous Injection versus Palonosetron Infusion for CINV Prevention: Cost Comparison of Unscheduled Hydration.American health & drug benefits · 2021Article
- Research Progress on the Antiemetic Effect of Traditional Chinese Medicine Against Chemotherapy-Induced Nausea and Vomiting: A Review.Frontiers in pharmacology · 2021Review
- An assay of drug-induced emesis in the squirrel monkey (Saimiri sciureus).Journal of medical primatology · 2019Article
- [Chemotherapy-induced nausea and vomiting : Current recommendations for prophylaxis].Der Urologe. Ausg. A · 2018Review
- Getting it right the first time: recent progress in optimizing antiemetic usage.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018Article
- Comparative investigation of the anti-emetic effects of granisetron and palonosetron during the treatment of acute myeloid leukemia.Molecular and clinical oncology · 2017Article
- Effectiveness of antiemetic triplet therapy with aprepitant, palonosetron, and dexamethasone for gynecologic cancer patients receiving carboplatin and paclitaxel: a prospective single-arm study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Article
- Antiemetic therapy for non-anthracycline and cyclophosphamide moderately emetogenic chemotherapy.Medical oncology (Northwood, London, England) · 2017Review
- Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NKSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Review
- Analysis of Dietary Intake during Consecutive-Day Chemotherapy for Bone and Soft-Tissue Sarcomas.Frontiers in nutrition · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePreventing chemotherapy-induced nausea and vomiting (CINV) is integral to treatment success in patients with cancer. This analysis was undertaken to assess the relative efficacy and safety of palonosetron versus older 5HT3 RAs in preventing CINV associated with moderately or highly emetogenic chemotherapy.
methodsPatient-level data from four randomized, double-blind, phase III trials comparing palonosetron 0.25 or 0.75 mg with ondansetron 32 mg, dolasetron 100 mg, or granisetron 40 μg/kg were analyzed. Endpoints included complete response (CR: no emesis and no rescue antiemetics) in the acute (0-24 h), delayed (>24-120 h), and overall (0-120 h) postchemotherapy periods (primary), complete control (CC: no emesis, no rescue antiemetics, and no more than mild nausea), number of emetic episodes, and nausea severity.
resultsCR rates were significantly higher for palonosetron (n = 1,787) versus older 5HT3 RAs (n = 1,175) in the delayed (57 vs 45 %, P < 0.0001) and overall periods (51 vs 40 %, P < 0.0001); odds ratios (95 % CI) in the acute, delayed, and overall periods were 1.15 (0.98-1.34), 1.62 (1.40-1.88), and 1.56 (1.34-1.81), respectively. Significant differences in CC rates and nausea severity were observed for the delayed and overall periods and in emetic episodes for all three periods. The incidence of treatment-related adverse events was similar with palonosetron (0.25 mg, 20.0 %; 0.75 mg, 26.5 %) and older 5HT3 RAs (27.5 %).
conclusionsPalonosetron is more effective than older 5HT3 RAs for controlling CINV in the delayed and overall postchemotherapy periods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.